{"id":958843,"date":"2026-05-06T08:04:05","date_gmt":"2026-05-06T12:04:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/"},"modified":"2026-05-06T08:04:05","modified_gmt":"2026-05-06T12:04:05","slug":"lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/","title":{"rendered":"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows"},"content":{"rendered":"

<\/p>\n

Lucent Diagnostics Announces Collaboration with Tempus<\/b>to Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows<\/b><\/p>\n

Agreement supports the identification of patients eligible for Alzheimer\u2019s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD\u00ae Complete on Tempus\u2019 clinical ordering platform<\/i><\/p>\n

BILLERICA, Mass.–(BUSINESS WIRE<\/a>)–
\nLucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer\u2019s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer\u2019s disease blood-based biomarker testing, with the LucentAD\u00ae<\/sup> Complete<\/a> multi-biomarker blood test becoming available for neurologists to order on the Tempus clinical ordering platform.<\/p>\n

More than 7 million Americans<\/a> are living with Alzheimer\u2019s disease today, yet only a small fraction are evaluated for eligibility for approved treatments. The collaboration aims to narrow that gap by embedding clinical guideline-directed identification and blood-based biomarker testing options directly into clinical decision-making workflows used by neurologists.<\/p>\n

\n\u201cThis collaboration represents an important step toward ensuring blood-based Alzheimer\u2019s biomarker testing becomes part of routine clinical practice \u2013 without placing additional burden on providers,\u201d said Everett Cunningham, CEO of Quanterix. \u201cBy working with Tempus to integrate LucentAD Complete into the clinical ordering workflow, we are helping reduce barriers to access and equipping neurologists with a more seamless, non-invasive approach to identifying amyloid-positive patients who may benefit from approved therapies. As we look to advance precision health through high-sensitivity biomarker innovation, collaborations that streamline the diagnostic journey are essential to support earlier, more confident clinical decisions.\u201d<\/p>\n

Tempus Next<\/a> is an AI-enabled care pathway intelligence platform that identifies care gaps and equips providers with actionable insights consistent with clinical guidelines at the point of care. While the Tempus Next Care Gap Program helps identify patients who may benefit from biomarker testing based on established clinical guidelines, clinicians have the option to order LucentAD Complete through existing EHR integrations.<\/p>\n

About Lucent Diagnostics
\n
<\/b>Lucent Diagnostics, a commercial brand of Quanterix, was created in 2023 to deliver revolutionary tools that aid in the earlier detection of cognitive disease. Powered by the ultra-sensitive Simoa\u00ae technology, Lucent Diagnostics bridges the gap between research and clinical use by offering products and services designed specifically to meet the separate needs of institutions and healthcare providers. With more than a decade of proven success within the neurology research space, supported by thousands of publications and partnerships, Quanterix aims to directly impact the landscape of cognitive disease through its commercial brand, Lucent Diagnostics. For more information, please visit www.LucentDiagnostics.com<\/a><\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix\u2019s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix\u2019s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix\u2019s filings with the U.S. Securities and Exchange Commission, including the \u201cRisk Factors\u201d sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260506938892\/en\/<\/a><\/span><\/p>\n

Quanterix Media Contact:
\n<\/b>
media@quanterix.com<\/a><\/p>\n

Investor Relations Contact:
\n<\/b>
Joshua Young
\n
(508) 846-3327
\n
jyoung@quanterix.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Health Technology Neurology Clinical Trials Artificial Intelligence Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows Agreement supports the identification of patients eligible for Alzheimer\u2019s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD\u00ae Complete on Tempus\u2019 clinical ordering platform BILLERICA, Mass.–(BUSINESS WIRE)– Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer\u2019s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer\u2019s disease blood-based biomarker testing, with the LucentAD\u00ae Complete multi-biomarker blood test becoming available … <\/p>\n

Continue reading “Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-958843","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows Agreement supports the identification of patients eligible for Alzheimer\u2019s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD\u00ae Complete on Tempus\u2019 clinical ordering platform BILLERICA, Mass.–(BUSINESS WIRE)– Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer\u2019s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer\u2019s disease blood-based biomarker testing, with the LucentAD\u00ae Complete multi-biomarker blood test becoming available … Continue reading "Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T12:04:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows\",\"datePublished\":\"2026-05-06T12:04:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/\"},\"wordCount\":660,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/\",\"name\":\"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-05-06T12:04:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/","og_locale":"en_US","og_type":"article","og_title":"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows - Market Newsdesk","og_description":"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows Agreement supports the identification of patients eligible for Alzheimer\u2019s disease biomarker testing through Tempus Next and enables neurologists to order LucentAD\u00ae Complete on Tempus\u2019 clinical ordering platform BILLERICA, Mass.–(BUSINESS WIRE)– Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, to broaden access to a novel blood-based biomarker panel designed to improve detection accuracy for Alzheimer\u2019s disease. Through the agreement, Tempus AI will build a Tempus Next care gap program for Alzheimer\u2019s disease blood-based biomarker testing, with the LucentAD\u00ae Complete multi-biomarker blood test becoming available … Continue reading \"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-06T12:04:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows","datePublished":"2026-05-06T12:04:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/"},"wordCount":660,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/","name":"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-05-06T12:04:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260506938892r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lucent-diagnostics-announces-collaboration-with-tempusto-integrate-blood-based-alzheimers-biomarker-testing-into-clinical-workflows\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lucent Diagnostics Announces Collaboration with Tempusto Integrate Blood-Based Alzheimer\u2019s Biomarker Testing into Clinical Workflows"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=958843"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958843\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=958843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=958843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=958843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}